Alzamend Neuro, Inc. (ALZN): Entry into a Material Definitive Agreement

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2026 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Agreement ”) with Ault Lending, LLC, a California limited liability

Event · Offering · closed
Instrument
Series D convertible preferred stock
Gross proceeds
$7.5 million
Shares
7,500 Preferred Shares
Also in this documentListing notice · deficiency

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 3, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ALZN
Neutral
medium confidence
Mentioned
$ALZN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALZNNeutralMed
01

Why it matters

A $25M preferred-stock financing can change the company’s capital structure and investor expectations. Traders will focus on dilution mechanics, conversion timing, and whether proceeds map to near-term catalysts.

02

Market read

Primary disclosure of a convertible preferred financing up to $25M aggregate, which can drive dilution and financing-risk repricing.

03

What to watch

Key trading drivers are missing from the excerpt, including conversion ratio/price, any beneficial ownership limits, investor participation rights, and whether proceeds fund specific clinical or regulatory milestones.

Relevance 6/10Novelty 8/10Timing: filed Aug 3, 2026 after-hours (8-K disclosure)

Background

The 8-K reports entry into a securities purchase agreement and an unregistered equity issuance, relying on exemptions from Securities Act registration.

Company-level read

Ticker impact

$ALZNNeutralMedium confidence
Context

Alzamend Neuro entered a material definitive securities purchase agreement to issue up to 25,000 shares of Series D convertible preferred stock.

Expected impact

Likely near-term volatility tied to dilution expectations and conversion terms, with direction dependent on discount/beneficial conversion mechanics not shown in the excerpt.

Evidence & confidence

The filing is a primary disclosure of a financing agreement size ($25M) and instrument type (convertible preferred). The excerpt does not include conversion price, discount, or investor rights, limiting precision on dilution magnitude and timing.

Market effects

Adds another small-cap biotech financing example, potentially reinforcing risk-off sentiment toward pre-commercial or development-stage issuers.

No clear regional spillover indicated by the excerpt.

Limited global relevance; this is company-specific private placement financing.

Counterpoint

If the preferred terms are favorable (e.g., limited conversion pressure, no aggressive reset), the deal could be viewed as runway extension rather than immediate dilution risk.

Key entities

  • Alzamend Neuro, Inc.

    Company filing the 8-K and entering the securities purchase agreement.

  • Ault Lending, LLC

    Counterparty purchasing up to 25,000 shares of Series D convertible preferred stock.

  • Series D Convertible Preferred Stock

    Convertible preferred instrument issued under the agreement, priced at $1,000 per share with stated value $1,050.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.